A detailed history of Vanguard Group Inc transactions in Unicycive Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 339,860 shares of UNCY stock, worth $220,909. This represents 0.0% of its overall portfolio holdings.

Number of Shares
339,860
Previous 115,057 195.38%
Holding current value
$220,909
Previous $100,000 369.0%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$0.83 - $1.79 $186,586 - $402,397
224,803 Added 195.38%
339,860 $469,000
Q1 2023

May 15, 2023

BUY
$0.44 - $2.68 $40,639 - $247,530
92,362 Added 406.97%
115,057 $241,000
Q4 2021

Feb 14, 2022

BUY
$1.81 - $3.05 $41,077 - $69,219
22,695 New
22,695 $47,000

Others Institutions Holding UNCY

About Unicycive Therapeutics, Inc.


  • Ticker UNCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,052,500
  • Market Cap $9.78M
  • Description
  • Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...
More about UNCY
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.